FR3112939B1 - Produit universel de thérapie cellulaire et son utilisation - Google Patents

Produit universel de thérapie cellulaire et son utilisation Download PDF

Info

Publication number
FR3112939B1
FR3112939B1 FR2008211A FR2008211A FR3112939B1 FR 3112939 B1 FR3112939 B1 FR 3112939B1 FR 2008211 A FR2008211 A FR 2008211A FR 2008211 A FR2008211 A FR 2008211A FR 3112939 B1 FR3112939 B1 FR 3112939B1
Authority
FR
France
Prior art keywords
cell therapy
cell
therapy product
universal cell
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2008211A
Other languages
English (en)
Other versions
FR3112939A1 (fr
Inventor
Martin Villalba
Christian Jorgensen
Bruno Robert
Pierre Martineau
Francisco Javier Hernandez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universite de Montpellier I
Universite de Montpellier
Original Assignee
Universite de Montpellier I
Universite de Montpellier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2008211A priority Critical patent/FR3112939B1/fr
Application filed by Universite de Montpellier I, Universite de Montpellier filed Critical Universite de Montpellier I
Priority to AU2021316729A priority patent/AU2021316729A1/en
Priority to CN202180067847.XA priority patent/CN116744946A/zh
Priority to KR1020237007319A priority patent/KR20230078632A/ko
Priority to JP2023507231A priority patent/JP2023535842A/ja
Priority to PCT/EP2021/071586 priority patent/WO2022023581A1/fr
Priority to CA3189963A priority patent/CA3189963A1/fr
Priority to EP21758336.8A priority patent/EP4188396A1/fr
Publication of FR3112939A1 publication Critical patent/FR3112939A1/fr
Application granted granted Critical
Publication of FR3112939B1 publication Critical patent/FR3112939B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4613—Natural-killer cells [NK or NK-T]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464403—Receptors for growth factors
    • A61K39/464406—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Produit universel de thérapie cellulaire et son utilisation Composition pharmaceutique comprenant une cellule NK (Natural Killer) ou un précurseur de cellule NK, en combinaison avec un polypeptide recombinant ; dans laquelle ledit polypeptide recombinant comprend (i) une région Fc (fragment cristallisable) modifiée, et (ii) un domaine de liaison à un ligand, ladite région Fc étant capable de se lier à ladite cellule NK ou à son précurseur. Figure pour l’abrégé : Néant
FR2008211A 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation Active FR3112939B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR2008211A FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation
CN202180067847.XA CN116744946A (zh) 2020-07-31 2021-08-02 用于通用细胞疗法的武装nk细胞
KR1020237007319A KR20230078632A (ko) 2020-07-31 2021-08-02 범용 세포 치료를 위한 무장된 nk 세포
JP2023507231A JP2023535842A (ja) 2020-07-31 2021-08-02 普遍的な細胞療法のための武装ｎｋ細胞
AU2021316729A AU2021316729A1 (en) 2020-07-31 2021-08-02 Armed NK cells for universal cell therapy
PCT/EP2021/071586 WO2022023581A1 (fr) 2020-07-31 2021-08-02 Cellules nk armées pour une thérapie cellulaire universelle
CA3189963A CA3189963A1 (fr) 2020-07-31 2021-08-02 Produit de therapie de cellule universelle et utilisation connexe
EP21758336.8A EP4188396A1 (fr) 2020-07-31 2021-08-02 Cellules nk armées pour une thérapie cellulaire universelle

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2008211A FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation
FR2008211 2020-07-31

Publications (2)

Publication Number Publication Date
FR3112939A1 FR3112939A1 (fr) 2022-02-04
FR3112939B1 true FR3112939B1 (fr) 2024-01-05

Family

ID=74095859

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2008211A Active FR3112939B1 (fr) 2020-07-31 2020-07-31 Produit universel de thérapie cellulaire et son utilisation

Country Status (8)

Country Link
EP (1) EP4188396A1 (fr)
JP (1) JP2023535842A (fr)
KR (1) KR20230078632A (fr)
CN (1) CN116744946A (fr)
AU (1) AU2021316729A1 (fr)
CA (1) CA3189963A1 (fr)
FR (1) FR3112939B1 (fr)
WO (1) WO2022023581A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115521913B (zh) * 2022-02-22 2023-07-25 北京景达生物科技有限公司 NK细胞与CD20、CD38、Her2抗体联合应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US64413A (en) 1867-05-07 Improvement in wagon-beake
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
AU1908395A (en) 1994-01-28 1995-08-15 Board Of Trustees Of The Leland Stanford Junior University Antibodies to mammalian natural killer antigens and uses
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
FR2915398B1 (fr) * 2007-04-25 2012-12-28 Lab Francais Du Fractionnement "ensemble de moyens pour le traitement d'une pathologie maligne, d'une maladie auto-immune ou d'une maladie infectieuse"
JP2017512765A (ja) * 2014-04-11 2017-05-25 メディミューン，エルエルシー 二重特異性ｈｅｒ２抗体
CN110475566A (zh) * 2017-02-02 2019-11-19 斯克里普斯研究学院 工程细胞和使用方法

Also Published As

Publication number Publication date
EP4188396A1 (fr) 2023-06-07
WO2022023581A1 (fr) 2022-02-03
AU2021316729A1 (en) 2023-03-02
KR20230078632A (ko) 2023-06-02
CA3189963A1 (fr) 2022-02-03
JP2023535842A (ja) 2023-08-21
FR3112939A1 (fr) 2022-02-04
CN116744946A (zh) 2023-09-12

Similar Documents

Publication Publication Date Title
Li et al. The role of progesterone receptors in breast cancer
Russell et al. Selepressin, a novel selective vasopressin V 1A agonist, is an effective substitute for norepinephrine in a phase IIa randomized, placebo-controlled trial in septic shock patients
Fleischmann Novel small-molecular therapeutics for rheumatoid arthritis
Haridas et al. Overexpression of the p80 TNF receptor leads to TNF-dependent apoptosis, nuclear factor-κB activation, and c-Jun kinase activation
FR3112939B1 (fr) Produit universel de thérapie cellulaire et son utilisation
Xu et al. Identification of O-GlcNAcylation modification in diabetic retinopathy and crosstalk with phosphorylation of STAT3 in retina vascular endothelium cells
Fultang et al. Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K/AKT/GSK3ß activity
Konala et al. Immunotherapy in bladder cancer
Bar-Shavit et al. Protease-activated receptors (PARs) in cancer: novel biased signaling and targets for therapy
Krause et al. Transient activation of Jun N-terminal kinases and protection from apoptosis by the insulin-like growth factor I receptor can be suppressed by dicumarol
Zehetner et al. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy
Rozen et al. Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology
Syed Daratumumab: a review in combination therapy for transplant-ineligible newly diagnosed multiple myeloma
Kim et al. The efficacy and safety of liquid-type botulinum toxin type A for the management of moderate to severe glabellar frown lines
von Drygalski et al. An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C
Rogers et al. Mutant anthrax toxin B moiety (protective antigen) inhibits angiogenesis and tumor growth
Huang et al. Fas and its ligand, caspases, and bcl-2 expression in gonadotropin-releasing hormone agonist-treated uterine leiomyoma
Yoon et al. Use of ulipristal acetate and risk of liver disease: a nationwide cohort study
Hillig et al. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor
King et al. No loose ends: a review of the pharmacotherapy of hairy cell and hairy cell leukemia variant
Arai et al. Aqueous humour proteins and treatment outcomes of anti-VEGF therapy in neovascular age-related macular degeneration
Nijm et al. AZR-MD-001 efficacy in resolving the signs and associated symptoms of meibomian gland dysfunction (MGD) in a phase 2 trial: responder status analysis
Vencio et al. Exploring early combination strategy in Latin American patients with newly diagnosed type 2 diabetes: a sub-analysis of the VERIFY study
Arnall et al. Comparative utilization and efficacy of thrombopoietin receptor agonists in relapsed/refractory immune thrombocytopenia
Bertelmann et al. Intravitreal thrombin activity is elevated in retinal vein occlusion

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20220204

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4